bedaquiline + delamanid + linezolid + levofloxacin + clofazimine

This is an investigational, all-oral combination regimen consisting of five drugs—bedaquiline, delamanid, linezolid, levofloxacin, and clofazimine—used for the treatment of multidrug-resistant tuberculosis (MDR-TB), including cases with additional resistance to fluoroquinolones or second-line injectables. Each component has a distinct mechanism of action targeting Mycobacterium tuberculosis. Bedaquiline inhibits mycobacterial ATP synthase; delamanid inhibits mycolic acid synthesis; linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit; levofloxacin is a fluoroquinolone that targets DNA gyrase and topoisomerase IV; and clofazimine binds to bacterial DNA and disrupts replication. This regimen aims to improve outcomes in MDR-TB patients by providing a potent oral alternative with reduced toxicity compared to traditional regimens. Clinical trials such as the DRAMATIC trial are evaluating its efficacy and optimal duration[1][6][7].

Other names

levofloxacin-Boston University-multidrug-resistant tuberculosisDRAMATIC Trial regimen5-drug MDR-TB regimen